Aktienanalyse zu Actinium Pharmaceuticals Inc (ATNM)ATNMActinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Actinium Pharmaceuticals Inc (ATNM) presents a compelling buy opportunity at the current price of $1.01 due to its recent strong earnings surprise of 545% and a significant projected upside of 342% based on analyst targets. The company has shown a remarkable turnaround with a net income of $27,901,000 in Q2 2026, indicating a strong recovery from previous losses. However, the main risk lies in the company's current liabilities, which have increased to $9,260,000 in Q2 2026, raising concerns about liquidity.

4 analysts cover ATNM: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 6.00.